Automatic Productivity for Life Science Discovery
News Mar 26, 2010
Agilent Automation Solutions has announced a 12-page brochure 'Automatic productivity for life science discovery' that provides an introduction to the company's complete range of automation solutions to increase the pace of discovery.
From high performance benchtop workstations to large, fully integrated systems - Agilent reliable automation platforms are available to speed-up cycle times and maximize productivity across the full spectrum of life science discovery applications including high throughput screening, compound management, high speed plate replication, genomic sample preparation, ADME-Tox assays, cell maintenance and processing as well as cell based screening.
A summary of product functionality together with key features and benefits is provided for liquid handling products including the Bravo Automated Liquid Handling Platform and the Agilent Vertical Pipetting Station. Along with liquid handling, microplate handling is at the heart of many discovery labs. An introduction is given for each of Agilent's integrated plate handling modules including the PlateLoc Thermal Microplate Sealer, Agilent Microplate Centrifuge, Microplate Barcode Labeler and Microplate Seal Piercer.
To meet the complete range of life science discovery application requirements the brochure also details Agilent Automation Solutions customizable scalable workstations and systems based upon the BenchCel Microplate Workstation, BioCel System and Agilent Direct Drive Robot.
Also described is Agilent's VWorks software that enables research enterprises to integrate a diverse group of devices such as robots, liquid handlers, readers, washers, and others to deliver a cohesive, integrated system that ensures maximum throughput and optimal resource utilization.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.